Your browser doesn't support javascript.
loading
Stereotactic body radiotherapy for early-stage non-small cell lung cancer: a multicentre study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)
Samper Ots, Pilar María; Vallejo Ocaña, C; Martin Martin, M; Celada Álvarez, F. J.; Farga Albiol, D; Almendros Blanco, P; Hernandez Machancoses, A; Rico Oses, M; Flamarique Andueza, S; Romero Ruperto, F.
Afiliación
  • Samper Ots, Pilar María; Hospital Universitario Rey Juan Carlos. Móstoles. Spain
  • Vallejo Ocaña, C; Hospital Universitario Ramón y Cajal. Madrid. Spain
  • Martin Martin, M; Hospital Universitario Ramón y Cajal. Madrid. Spain
  • Celada Álvarez, F. J.; Hospital Universitario y Politécnico La Fe. Valencia. Spain
  • Farga Albiol, D; Hospital Universitario y Politécnico La Fe. Valencia. Spain
  • Almendros Blanco, P; Hospital General de Valencia. Valencia. Spain
  • Hernandez Machancoses, A; Hospital General de Valencia. Valencia. Spain
  • Rico Oses, M; Complejo Hospitalario de Navarra. Navarra. Spain
  • Flamarique Andueza, S; Complejo Hospitalario de Navarra. Navarra. Spain
  • Romero Ruperto, F; Hospital Universitario Reina Sofía. Córdoba. Spain
Clin. transl. oncol. (Print) ; Clin. transl. oncol. (Print);24(2): 342-349, febrero 2022.
Article en En | IBECS | ID: ibc-203439
Biblioteca responsable: ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
Purpose/objective(s)Stereotactic body radiotherapy (SBRT) has become the standard of care for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) and for patients who refuse surgery. The aim of this study was to evaluate the effectiveness and safety of primary SBRT in patients with early-stage NSCLC.Materials/methodsRetrospective multicenter study of 397 patients (416 primary lung tumours) treated with SBRT at 18 centres in Spain. 83.2% were men. The median age was 74.4 years. In 94.4% of cases, the tumour was inoperable. The pathological report was available in 54.6% of cases. SPSS vs 22.0. was used to perform all statistical analyses.ResultsComplete response was obtained in 53.6% of cases. Significant prognostic factors were standard CT planning (p = 0.014) and 4D cone beam CT (p = 0.000). Acute and chronic toxicity ≥ grade 3 was observed in 1.2% of cases. At a median follow-up of 30 months, local relapse was 9.6%, lymph node relapse 12.8%, distant metastasis 16.6%, and another lung tumour 11.5%. Complete response was the only significant prognostic factor for local relapse (p = 0.012) and distant metastasis (p = 0.001). The local relapse-free survival was 88.7%. The overall survival was 75.7%. The cancer-specific survival was 92.7%. The disease-free survival was 78.7%.ConclusionSBRT is an effective and well-tolerated treatment option for patients with early-stage lung cancer who are not suitable for surgery. The most important prognostic factor for local and distant recurrence was complete response, which in our sample depended on the type of CT planning and the IGRT technique.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google

Texto completo: 1 Colección: 06-national / ES Base de datos: IBECS Asunto principal: Radioterapia / Carcinoma de Pulmón de Células no Pequeñas / 35514 / Ciencias de la Salud / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google

Texto completo: 1 Colección: 06-national / ES Base de datos: IBECS Asunto principal: Radioterapia / Carcinoma de Pulmón de Células no Pequeñas / 35514 / Ciencias de la Salud / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2022 Tipo del documento: Article